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During the past few decades, cancer therapy was based on the
classical options of surgery, radiation and chemotherapy. And
although there are examples where these techniques are applied
with great success, there is still a lack of good treatment options for
the most common types of cancer, especially in advanced cases
with distant organ metastasis.
During the last 20 years, basic research has considerably
expanded our understanding of tumour biology. It has become
obvious that cancer development and progression consists of
several consecutive steps, and many molecular key events have
been identified. One of the most important changes in our view of
cancer in general was that we noticed the importance of tumour–
host interactions. There is a constant cross-talk between tumour
cells on one side and the surrounding stroma and immune cells on
the other side. This is most obvious for tumour angiogenesis, but
there are several other examples like the contribution of fibroblasts
to the proteolytic capacity of the tumour or the various immune
escape mechanisms used by the neoplastic cells to circumvent
attack by the immune system.
Currently, several new approaches based on these discoveries
are trying to make the step from laboratory to clinic. Many
promising results were obtained from in vitro and animal
experiments, indicating that specific disturbances in tumour–host
interactions might slow down the progression of malignant
disease. Therefore, it is challenging for everyone working in the
field of oncology to keep up with the newest developments of
anticancer strategies.
‘Cancer Therapy-Molecular Targets in Tumour-Host Inter-
actions’ provides in 16 chapters examples of molecular key events
and mechanisms during tumour progression, which might be
targeted to interfere with malignant progression. Special emphasis
is put on antiangiogenesis to prevent the formation of new blood
vessels, leading to reduced tumour growth due to a lack of oxygen
and nutrients. Most articles cite the literature until 2004, which is
sufficient to cover newer developments.
Our main criticism concerning this book is that the reader does
not really get an overview of the field. The preface by Georg F
Weber is written well and leads into the field, but it is too short to
really connect the following parts. The single chapters, all written
by different authors, focus on very specialised topics, but largely
fail to cover the broader field.
There is no common format, and some chapters resemble more
lab protocols. The length of the different articles varies consider-
ably between 10 and 50 pages, and at least to us it is not obvious on
which criteria the different aspects of the field were weighted. One
of the major shortcomings is the far too low number of figures.
These could have been used to facilitate reading and under-
standing of the topics, especially for readers not working in the
particular fields.
In summary, this book contains some interesting articles
addressing specialised fields of research, and therefore it might
be useful to readers searching for distinct topics. But we cannot
recommend it for readers who want to get an overview over the
field. The approach is not systematic enough and the single
chapters focus too much on certain aspects, not covering the whole
field in review style. Therefore, this book appears to be suitable
only to a specialised audience.
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